Top

BY Clayton Boldt, Ph. D.

Repurposing FDA-approved therapies is a cost-effective way to bring new treatments to patients in need, but identifying those drugs with benefits in new indications can be a challenging discovery process.

A team of researchers led by MD Anderson and the IRCCS Regina Elena National Cancer Institute in Rome have used a novel computer-aided drug discovery approach to identify decitabine, an FDA approved therapy for myelodysplastic...

Gene expression signature identified in the study allows pancreatic cancers stratification based on KRAS dependency

BY Ron Gilmore

The addition of nivolumab to induction chemotherapy with idarubicin and cytarabine is feasible in patients with newly diagnosed acute myeloid...

BY Clayton Boldt, Ph.D.

Leukemia researchers at The University of Texas MD Anderson Cancer Center, working collaboratively with the Therapeutics Discovery division...

BY Jill Russell, Ph.D.

Researchers at The University of Texas MD Anderson Cancer Center have shown how pretreatment clonal complexity in pancreatic tumor cells leads to chemotherapy resistance, findings that could lead to better-personalized and effective combination therapies.

Tumorigenesis is an evolutionary process. “A tumor is an ecosystem composed of different cell populations, and the fittest survive,” says Alessandro Carugo, Ph.D., research scientist...

Pancreatic cancer cells

BY Jill Russell, Ph.D.

Immunology research to investigate the mechanisms of a new aerosol treatment, which induces an innate immune response to protect against pathogens...

BY Clayton R. Boldt, Ph.D.

Chronic lymphocytic leukemia (CLL), which originates in white blood cells known as lymphocytes, is the most common form of leukemia in adults...

BY Ron Gilmore

Researchers in MD Anderson’s Leukemia department played central roles in the studies of two drugs, glasdegib and venetoclax, approved in November...

BY Clayton R. Boldt, Ph.D.

MD Anderson’s Moon Shots Program™ was established to bring teams of world-class clinicians and researchers together in order to rapidly advance...

BY Ron Gilmore

Somatic mutations in certain genes may function as a molecular minimal residual disease marker for acute myeloid leukemia (AML), according...

BY Clayton R. Boldt, Ph.D.

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) encompass a spectrum of diseases characterized by an overproduction of immature...